Atopic dermatitis (AD) is a chronic inflammatory skin disease often preceding asthma and allergies. It is associated with structural epidermal abnormalities and immune dysregulation. Patients with AD are prone to microbial infections, particularly by Staphylococcus aureus and herpes simplex virus. Healing the skin barrier and addressing immune dysregulation are crucial for treatment. Genetic studies show AD has a strong hereditary component, with genes like FLG (filaggrin) playing a key role. Mutations in FLG are strongly linked to AD and increase susceptibility to infections. AD is also associated with asthma and allergies, with immune dysregulation contributing to these conditions. Recent studies highlight the role of TSLP in AD and its complications. The skin barrier dysfunction in AD allows microbial colonization and infection, contributing to severe outcomes. Therapeutic strategies targeting the skin barrier and immune system, such as calcineurin inhibitors and vitamin D, show promise. New approaches, including vaccines and antimicrobial peptides, are being explored to combat microbial infections in AD. Understanding the complex interplay between skin barrier and immune abnormalities is essential for developing targeted therapies for AD and its complications.Atopic dermatitis (AD) is a chronic inflammatory skin disease often preceding asthma and allergies. It is associated with structural epidermal abnormalities and immune dysregulation. Patients with AD are prone to microbial infections, particularly by Staphylococcus aureus and herpes simplex virus. Healing the skin barrier and addressing immune dysregulation are crucial for treatment. Genetic studies show AD has a strong hereditary component, with genes like FLG (filaggrin) playing a key role. Mutations in FLG are strongly linked to AD and increase susceptibility to infections. AD is also associated with asthma and allergies, with immune dysregulation contributing to these conditions. Recent studies highlight the role of TSLP in AD and its complications. The skin barrier dysfunction in AD allows microbial colonization and infection, contributing to severe outcomes. Therapeutic strategies targeting the skin barrier and immune system, such as calcineurin inhibitors and vitamin D, show promise. New approaches, including vaccines and antimicrobial peptides, are being explored to combat microbial infections in AD. Understanding the complex interplay between skin barrier and immune abnormalities is essential for developing targeted therapies for AD and its complications.